Key Points
- Executive vice president Shannon Parisotto sold 981 CRL shares for approximately $302,580 at an average price of $308.44, reducing her position by 16.95%. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
- Charles River Laboratories reported quarterly EPS of $3.02, exceeding the $2.77 consensus estimate, while revenue reached $1 billion. However, revenue declined 2.7% year over year and the company reported a negative net margin.
- Analyst sentiment remains favorable, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $300.11; several firms recently raised their targets to as high as $330.
Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) EVP Shannon Parisotto sold 981 shares of the stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $308.44, for a total transaction of $302,579.64. Following the sale, the executive vice president owned 4,807 shares of the company's stock, valued at $1,482,671.08. This trade represents a 16.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Charles River Laboratories International Price Performance
NYSE:CRL opened at $300.21 on Thursday. The firm has a market cap of $14.33 billion, a PE ratio of -61.90, a price-to-earnings-growth ratio of 2.86 and a beta of 1.40. Charles River Laboratories International, Inc. has a 12 month low of $146.20 and a 12 month high of $333.30. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.92. The company's 50-day moving average price is $281.78 and its two-hundred day moving average price is $221.18.
Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The firm had revenue of $1 billion for the quarter, compared to analysts' expectations of $980.53 million. During the same period in the prior year, the firm earned $3.12 earnings per share. The company's quarterly revenue was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, equities analysts anticipate that Charles River Laboratories International, Inc. will post 11.36 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities research analysts have weighed in on the stock. TD Cowen raised their price objective on shares of Charles River Laboratories International from $300.00 to $325.00 and gave the company a "buy" rating in a research report on Friday, September 25th. Piper Sandler set a $300.00 price target on shares of Charles River Laboratories International in a research note on Monday, August 10th. Argus set a $330.00 price target on shares of Charles River Laboratories International in a report on Thursday, September 17th. Barclays boosted their price objective on shares of Charles River Laboratories International from $300.00 to $330.00 and gave the stock an "overweight" rating in a research report on Friday, September 25th. Finally, BNP Paribas Exane set a $250.00 price objective on Charles River Laboratories International in a report on Wednesday, July 1st. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Charles River Laboratories International presently has an average rating of "Moderate Buy" and an average price target of $300.11.
Get Our Latest Analysis on Charles River Laboratories International
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of CRL. Amundi raised its stake in shares of Charles River Laboratories International by 175.2% during the first quarter. Amundi now owns 773,315 shares of the medical research company's stock worth $133,397,000 after buying an additional 492,301 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Charles River Laboratories International by 14.6% in the first quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company's stock valued at $285,001,000 after acquiring an additional 210,260 shares during the last quarter. Empyrean Capital Partners LP bought a new position in Charles River Laboratories International in the fourth quarter valued at approximately $24,237,000. Clearbridge Investments LLC grew its holdings in Charles River Laboratories International by 23.0% during the 4th quarter. Clearbridge Investments LLC now owns 511,618 shares of the medical research company's stock worth $102,058,000 after acquiring an additional 95,619 shares during the period. Finally, Public Employees Retirement Association of Colorado raised its position in shares of Charles River Laboratories International by 1,558.6% during the 4th quarter. Public Employees Retirement Association of Colorado now owns 83,643 shares of the medical research company's stock valued at $16,685,000 after acquiring an additional 78,600 shares during the last quarter. Institutional investors own 98.91% of the company's stock.
Trending Headlines about Charles River Laboratories International
Here are the key news stories impacting Charles River Laboratories International this week:
- Positive Sentiment: Analysts raised earnings forecasts. Zacks Research increased its FY2026 EPS estimate to $11.17 from $11.15, FY2027 to $12.54 from $12.49, and FY2028 to $13.92 from $13.82. It also made modest upward revisions to several quarterly estimates and maintained a “Strong-Buy” rating. Zacks Research earnings forecast
- Positive Sentiment: UBS upgraded CRL to Strong Buy, providing additional institutional support after the company’s substantial 12-month advance. UBS upgrade
- Positive Sentiment: Operational momentum remains a key bullish theme. Recent coverage points to improving Research Models and Services trends, expanding AI-enabled testing, healthy cash flow, and the ability to fund share buybacks and investment. Charles River rally analysis
- Positive Sentiment: Charles River and Autolomous launched Apollo Orchestrate, a digital laboratory-execution solution integrated within Charles River’s Apollo platform. The initiative could strengthen the company’s technology offering and improve laboratory efficiency. Apollo Orchestrate launch
- Neutral Sentiment: A Zacks comparison examines whether CRL or Progyny offers the more attractive value opportunity. The article may influence valuation-focused investors, but the headline does not disclose a definitive preference. PGNY versus CRL value analysis
- Negative Sentiment: Valuation and recent gains may be limiting near-term upside. With CRL near its 12-month high after a powerful rally, investors may be taking profits while awaiting further earnings confirmation. The company’s latest reported revenue declined 2.7% year over year, adding a reason for caution despite earnings beating estimates.
Charles River Laboratories International Company Profile
(
Get Free Report)
Charles River Laboratories International, Inc is a contract research organization that provides products and services to support pharmaceutical, biotechnology and academic research. The company helps customers discover, develop and manufacture new medicines, vaccines and other healthcare products.
Its offerings include research models and related services, preclinical drug discovery, pharmacology, toxicology, bioanalysis and safety assessment. Charles River also provides laboratory and manufacturing solutions for biologics, cell and gene therapies, microbial testing and other specialized life sciences applications.
Founded in 1947, Charles River Laboratories serves customers worldwide through operations across North America, Europe and Asia.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
